Literature DB >> 10603393

Enhanced production of recombinant Mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons.

D L Lakey1, R K Voladri, K M Edwards, C Hager, B Samten, R S Wallis, P F Barnes, D S Kernodle.   

Abstract

A major obstacle to development of subunit vaccines and diagnostic reagents for tuberculosis is the inability to produce large quantities of these proteins. To test the hypothesis that poor expression of some mycobacterial genes in Escherichia coli is due, in part, to the presence of low-usage E. coli codons, we used site-directed mutagenesis to convert low-usage codons to high-usage codons for the same amino acid in the Mycobacterium tuberculosis genes for antigens 85A and 85B and superoxide dismutase. Replacement of five codons in the wild-type gene for antigen 85B increased recombinant protein production in E. coli 54-fold. The recombinant antigen elicited proliferation and gamma interferon production by lymphocytes from healthy tuberculin reactors and was recognized by monoclonal antibodies to native antigen 85, indicating that the recombinant antigen contained T-cell and B-cell epitopes. Northern blotting demonstrated only a 1.7- to 2.5-fold increase in antigen 85B mRNA, suggesting that the enhanced protein production was due primarily to enhanced efficiency of translation. Codon replacement in the genes encoding antigen 85A and superoxide dismutase yielded four- to sixfold increases in recombinant protein production, suggesting that this strategy may be generally applicable to overexpression of mycobacterial genes in E. coli.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10603393      PMCID: PMC97126          DOI: 10.1128/IAI.68.1.233-238.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Purification and characterization of the 30,000 dalton native antigen of Mycobacterium tuberculosis and characterization of six monoclonal antibodies reactive with a major epitope of this antigen.

Authors:  R A Salata; A J Sanson; I J Malhotra; H G Wiker; M Harboe; N B Phillips; T M Daniel
Journal:  J Lab Clin Med       Date:  1991-12

2.  Specific endonucleolytic cleavage sites for decay of Escherichia coli mRNA.

Authors:  V J Cannistraro; M N Subbarao; D Kennell
Journal:  J Mol Biol       Date:  1986-11-20       Impact factor: 5.469

3.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

4.  High-level heterologous expression and secretion in rapidly growing nonpathogenic mycobacteria of four major Mycobacterium tuberculosis extracellular proteins considered to be leading vaccine candidates and drug targets.

Authors:  G Harth; B Y Lee; M A Horwitz
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  The genes coding for the antigen 85 complexes of Mycobacterium tuberculosis and Mycobacterium bovis BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of M. tuberculosis.

Authors:  J Content; A de la Cuvellerie; L De Wit; V Vincent-Levy-Frébault; J Ooms; J De Bruyn
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

6.  Cloning and expression of the Mycobacterium bovis BCG gene for extracellular alpha antigen.

Authors:  K Matsuo; R Yamaguchi; A Yamazaki; H Tasaka; T Yamada
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

7.  Low-usage codons in Escherichia coli, yeast, fruit fly and primates.

Authors:  S P Zhang; G Zubay; E Goldman
Journal:  Gene       Date:  1991-08-30       Impact factor: 3.688

8.  Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis.

Authors:  Y Zhang; R Lathigra; T Garbe; D Catty; D Young
Journal:  Mol Microbiol       Date:  1991-02       Impact factor: 3.501

9.  Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons.

Authors:  A J Makoff; M D Oxer; M A Romanos; N F Fairweather; S Ballantine
Journal:  Nucleic Acids Res       Date:  1989-12-25       Impact factor: 16.971

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  21 in total

1.  Inhibition of translation by consecutive rare leucine codons in E. coli: absence of effect of varying mRNA stability.

Authors:  Ping Shu; Huacheng Dai; Wenwu Gao; Emanuel Goldman
Journal:  Gene Expr       Date:  2006

2.  Class II MHC antigen presentation defect in neonatal monocytes is not correlated with decreased MHC-II expression.

Authors:  David H Canaday; Soma Chakravarti; Tarun Srivastava; Daniel J Tisch; Vinay K Cheruvu; Jamie Smialek; Clifford V Harding; Lakshmi Ramachandra
Journal:  Cell Immunol       Date:  2007-02-26       Impact factor: 4.868

3.  Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against Mycobacterium tuberculosis.

Authors:  Shuai Shi; Lan Yu; Dengyun Sun; Jian Liu; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-10-28       Impact factor: 4.200

4.  Cyclipostins and cyclophostin analogs inhibit the antigen 85C from Mycobacterium tuberculosis both in vitro and in vivo.

Authors:  Albertus Viljoen; Matthias Richard; Phuong Chi Nguyen; Patrick Fourquet; Luc Camoin; Rishi R Paudal; Giri R Gnawali; Christopher D Spilling; Jean-François Cavalier; Stéphane Canaan; Mickael Blaise; Laurent Kremer
Journal:  J Biol Chem       Date:  2018-01-04       Impact factor: 5.157

5.  Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.

Authors:  Daimon P Simmons; Pamela A Wearsch; David H Canaday; Howard J Meyerson; Yi C Liu; Ying Wang; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

6.  A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice.

Authors:  Haniyeh Aghababa; Ashraf Mohabati Mobarez; Nima Khoramabadi; Mehrdad Behmanesh; Mehdi Mahdavi; Majid Tebianian; Mehdi Nejati
Journal:  Mol Biotechnol       Date:  2014-06       Impact factor: 2.695

7.  Procedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytes.

Authors:  Xian-Hui He; Li-Hui Xu; Yi Liu
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

8.  Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Pavan Muttil; Danielle Padilla; Ding Xu; Jian Liu; Miriam Braunstein; David N McMurray; Anthony James Hickey
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

9.  High level expression of recombinant Mycobacterium tuberculosis culture filtrate protein CFP32 in Pichia pastoris.

Authors:  C Benabdesselem; M R Barbouche; M A Jarboui; K Dellagi; J L Ho; D M Fathallah
Journal:  Mol Biotechnol       Date:  2007-01       Impact factor: 2.695

10.  The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.

Authors:  Adam J Gehring; Roxana E Rojas; David H Canaday; David L Lakey; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.